• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24840 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concizumab (haemophilia A) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (nasopharyngeal carcinoma) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (small cell lung cancer, extensive stage) – Benefit assessment according to §35a Social Code Book V]
2025     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety and efficacy of guided imagery for the control of chronic pain]
2025     Basque Office for Health Technology Assessment (OSTEBA) [CT-guided percutaneous ablation for lung metastasis using radiofrequency or microwaves in patients who are not eligible for curative local and/ or systemic treatment]
2025     Basque Office for Health Technology Assessment (OSTEBA) [Magnetic nanoparticles and a magnetic field generator for inducing hyperthermia in the treatment of pancreatic cancer]
2025     Basque Office for Health Technology Assessment (OSTEBA) [Efficacy and safety of non-invasive brain stimulation therapies for the neurorehabilitation of patients with stroke]
2025     Basque Office for Health Technology Assessment (OSTEBA) [Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of children with peritoneal carcinomatosis]
2025     Basque Office for Health Technology Assessment (OSTEBA) [Effectiveness and safety of adaptive radiation therapy in patients with lymphoma, head and neck cancer or lung carcinoma]
2025     Basque Office for Health Technology Assessment (OSTEBA) [Intrasaccular device for endovascular treatment of cerebral aneurysm]
2025     Basque Office for Health Technology Assessment (OSTEBA) [Intraoperative fluorescence imaging for cancer cell identification]
2025     Basque Office for Health Technology Assessment (OSTEBA) [Cardiovascular monitoring systems using photoplethysmography]
2025     Basque Office for Health Technology Assessment (OSTEBA) [Intestinal ultrasound in inflammatory bowel disease: diagnostic effectiveness, cost-effectiveness and patient and health professional perspectives]
2025     Basque Office for Health Technology Assessment (OSTEBA) [3D printing in traumatology, cardiology, vascular surgery, maxillofacial surgery, neurosurgery, joint injuries, and bone repair]
2025     Agenzia nazionale per i servizi sanitari regionali (Agenas) Robotic surgery systems in general surgery, gynecology, and urology
2025     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of extending population-based breast cancer screening to women aged 45–49 and 70–74 and the use of digital breast tomosynthesis in screening women with dense breast tissue]
2025     National Institute for Health and Care Excellence (NICE) Slide sheets for moving or repositioning a person: late-stage assessment. NICE HealthTech guidance 745
2025     National Institute for Health and Care Excellence (NICE) Drug-eluting stents for treating coronary artery disease: late-stage assessment. NICE HealthTech guidance 747
2025     National Institute for Health and Care Excellence (NICE) Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment. NICE HealthTech guidance 751
2025     National Institute for Health and Care Excellence (NICE) Intermittent urethral catheters for chronic incomplete bladder emptying in adults: late-stage assessment. NICE HealthTech guidance 753
2025     National Institute for Health and Care Excellence (NICE) One-piece closed bags for colostomies: late-stage assessment. NICE HealthTech guidance 754
2025     National Institute for Health and Care Excellence (NICE) Transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis: late-stage assessment. NICE HealthTech guidance 757
2025     National Institute for Health and Care Excellence (NICE) Bed frames for adults in acute medical or surgical hospital wards: late-stage assessment. NICE HealthTech guidance 759
2025     National Institute for Health and Care Excellence (NICE) Compression products for treating venous leg ulcers: late-stage assessment. NICE HealthTech guidance 758
2025     National Institute for Health and Care Excellence (NICE) Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care: early value assessment. NICE HealthTech guidance 739
2025     National Institute for Health and Care Excellence (NICE) Robot-assisted surgery for orthopaedic procedures: early value assessment. NICE HealthTech guidance 743
2025     National Institute for Health and Care Excellence (NICE) Robot-assisted surgery for soft tissue procedures: early value assessment. NICE HealthTech guidance 742
2025     National Institute for Health and Care Excellence (NICE) Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessment. NICE HealthTech guidance 746
2025     National Institute for Health and Care Excellence (NICE) Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment. NICE HealthTech guidance 748
2025     National Institute for Health and Care Excellence (NICE) Digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments: early value assessment. NICE HealthTech guidance 756
2025     National Institute for Health and Care Excellence (NICE) Artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures: early value assessment. NICE HealthTech guidance 760
2025     National Institute for Health and Care Excellence (NICE) Digital platforms to support cardiac rehabilitation: early value assessment. NICE HealthTech guidance 761
2025     Scottish Health Technologies Group (SHTG) Esaote® extremity MRI scanners
2025     Agency of Health Technology Assessment of Uruguay (AETSU) [iSGLT2 in the treatment of chronic kidney disease]
2025     Agency of Health Technology Assessment of Uruguay (AETSU) [iSGLT2 in the treatment of heart failure]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Population grouping methodology Pop-Grouper and its use by the National Institute of Excellence in Health and Social Services]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Algorithm for the management of complex regional pain syndrome (CRPS)]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Virtual gene panels associated with epilepsy with or without neurodevelopmental disorders analyzed using next-generation exome sequencing: repatriation of an analysis performed outside of the province of Quebec]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Economic evaluations of kidney transplantation strategies for eligible individuals in high-income countries]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Portrait of the Quebec trauma care network: 2016-2022]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Support services for informal caregivers who assist community-dwelling seniors with significant loss of autonomy]
2025     HTA South [Screening for diabetic retinopathy with artificial intelligence for image analysis: a systematic review and assessment of medical, economical, ethical and organisational aspects]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Appropriate use of laboratory tests - 25-OH vitamin D testing]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Appropriate use of laboratory tests - bleeding time (in vivo)]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Appropriate use of laboratory tests - direct bilirubin testing]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Appropriate use of laboratory tests - aspartate aminotransferase testing in the investigation of liver injury]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Interventions to quit smoking (or vaping)]
2025     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of Capivasertib (Truqap)]
2025     Haute Autorite de sante (HAS) [Evaluation of five dentistry procedures (3 reports) : atraumatic restorative treatment, therapeutic sealing, silver diamine fluoride application, preformed paediatric crown, therapeutic pulpotomy in mature permanent teeth]
2025     Austrian Institute for Health Technology Assessment (AIHTA) Guidance for searching and finding public contributions to pharmaceutical R&D
2025     Austrian Institute for Health Technology Assessment (AIHTA) Telecardiology for heart failure patients: Benefit assessment and evaluation concept for telemedicine-supported care programmes in Austria
2025     Austrian Institute for Health Technology Assessment (AIHTA) Nudging interventions to optimise physician prescribing behaviour
2025     The Regional Health Technology Assessment Centre (HTA-centrum) Cervical length screening followed by progesterone with or without additional treatment for short cervix to prevent preterm birth
2025     The Regional Health Technology Assessment Centre (HTA-centrum) Radiofrequency or microwave ablation versus surgery for treatment of benign non-toxic or toxic nodules, and toxic diffuse autoimmune hyperthyroidism (Graves' disease)
2025     The Regional Health Technology Assessment Centre (HTA-centrum) Benefits and risks of hospital at home compared with in-hospital care according to current Swedish healthcare routine
2025     The Regional Health Technology Assessment Centre (HTA-centrum) Efficacy and safety of parenteral clomipramine compared to oral clomipramine or other treatments for depression or obsessive-compulsive disorder
2025     WorkSafeBC Magnesium to treat chronic pain
2025     WorkSafeBC Arthrosamid® in treating knee osteoarthritis (OA)
2025     WorkSafeBC Efficacy / effectiveness of Ubiquinol® in treating chronic fatigue syndromes post acute COVID-19 syndromes
2025     WorkSafeBC Efficacy/effectiveness of Vyvanse® in treating chronic fatigue syndromes (CFS) or post acute COVID-19 syndromes
2025     WorkSafeBC Efficacy and / or effectiveness of SportVis as treatment for subacromial bursitis - 2025 update
2025     WorkSafeBC Platelet rich plasma in treating disc herniation or facet joint pain
2025     WorkSafeBC Cryotherapy in treating meniscal tears
2025     WorkSafeBC Combining IV and oral ketamine to treat chronic non-cancer pain
2025     WorkSafeBC Complex regional pain syndrome (CRPS) diagnostic criteria at time of evaluation and its role on treatment outcomes
2025     WorkSafeBC Red light therapy for Achilles / other tendon rupture
2025     WorkSafeBC Effectiveness of extra corporeal shockwave therapy (ESWT) in treating biceps tendinopathy
2025     WorkSafeBC Firefighting and coronary heart disease
2025     WorkSafeBC CRPS and dental pain/sensitivity
2025     WorkSafeBC Traumatic brain injury (TBI) without any ocular trauma and cataract development
2025     WorkSafeBC Pulsed electromagnetic field therapy (PEMF), hyperbaric chamber, or acupuncture for treatment of hypersensitivity pneumonitis
2025     WorkSafeBC Meniscal injury and time to TKA: partial meniscectomy vs. conservative treatment
2025     WorkSafeBC Industrial instrument mechanic and development of multiple myeloma
2025     WorkSafeBC The effects of Sb2O3 [antimony trioxide] on human health
2025     WorkSafeBC Tower crane operators and low back pain
2025     WorkSafeBC Firefighting and Crohn’s disease
2025     WorkSafeBC Aerolase® System in treating burn/scar tissue
2025     WorkSafeBC IV ketamine therapy for long Covid
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Regulation and clinical prioritization processes for the optimal deployment of a helicopter emergency medical transport system in Quebec]
2025     The Regional Health Technology Assessment Centre (HTA-centrum) Maternal and perinatal mortality and severe morbidity of midwife assisted births outside hospital compared with hospital births
2025     The Regional Health Technology Assessment Centre (HTA-centrum) Dental assessment for prevention of medication-related osteonecrosis of the jaw in adults with early breast cancer
2025     Austrian Institute for Health Technology Assessment (AIHTA) Obecabtagene autoleucel (AUCATZYL®) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia
2025     Austrian Institute for Health Technology Assessment (AIHTA) Social prescribing in primary care. Development of an Austrian programme theory based on realist evidence
2025     Austrian Institute for Health Technology Assessment (AIHTA) Further development of the programme on preventive medical check-ups in Austria. Risk scores for cardiovascular disease: a systematic review
2025     Austrian Institute for Health Technology Assessment (AIHTA) Further development of the programme on preventive health check-ups in Austria. Brief interventions for lifestyle counselling: umbrella review and qualitative survey
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Antibiotic prophylaxis in digestive tract and abdominal wall surgery]
2025     National Institute for Health and Care Excellence (NICE) VA ECMO for postcardiotomy cardiogenic shock in adults. NICE interventional procedures guidance 810
2025     National Institute for Health and Care Excellence (NICE) Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments. NICE technology appraisal guidance 1114
2025     National Institute for Health and Care Excellence (NICE) Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma. NICE technology appraisal guidance 1113
2025     National Institute for Health and Care Excellence (NICE) Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy. NICE technology appraisal guidance 1115
2025     National Institute for Health and Care Excellence (NICE) Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia. NICE technology appraisal guidance 1116
2025     National Institute for Health and Care Excellence (NICE) Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency. NICE technology appraisal guidance 1117
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Use of prescription opioids for pain in Quebecers aged 65 years and older]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (mantle cell lymphoma; combination with bendamustine and rituximab) – Addendum to Project A25-89]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (oesophageal or gastro-oesophageal junction cancer, adjuvant) – Addendum to Project A25-88]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (colorectal cancer with dMMR or MSI-H, first line, combination with ipilimumab) – Addendum to Project A25-80]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Resmetirom (metabolic dysfunction-associated steatohepatitis) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avacopan (granulomatosis with polyangiitis or microscopic polyangiitis) – Benefit assessment according to §35a Social Code Book V]